C4 Therapeutics, Inc. Cash Flow Statement
CCCC|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
C4 Therapeutics, Inc. used $99M in operating cash flow and negative free cash flow of $99M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$105.0M | -$132.5M | -$132.5M | -$83.9M |
| Depreciation & Amortization | $2.0M | $1.9M | $1.9M | $1.5M |
| Operating Cash Flow | -$98.7M | -$106.8M | -$106.8M | -$87.0M |
| Capital Expenditures | $607.0K | $1.7M | $1.7M | $1.3M |
| Free Cash Flow | -$99.3M | -$108.5M | -$108.5M | -$88.2M |
| Share Buybacks | $193.0K | $110.0K | $110.0K | - |
| FCF Margin | -276.2% | -523.0% | -523.0% | -192.7% |